المواطنين من كبار السن حكمة موضه naturally occurring antibodies devoid of light chains تعال إلى الأعلى مع يصلح خليط
Landscape of Variable Domain of Heavy-chain-only Antibody Repertoire from Alpaca
Slaying SARS-CoV-2 One (Single-domain) Antibody at a Time: Trends in Microbiology
Frontiers | Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics | Immunology
A bispecific IgG format containing four independent antigen binding sites | Scientific Reports
2021.06.04.31 - Bionatura
Cells | Free Full-Text | Shark New Antigen Receptor (IgNAR): Structure, Characteristics and Potential Biomedical Applications | HTML
Nanobodies: new avenue to treat kidney disease | SpringerLink
Immunoglobulin light chain - Wikipedia
Sources of antibody variable chains - ScienceDirect
Free immunoglobulin light chain: Its biology and implications in diseases - ScienceDirect
Full article: Nanobodies: their potential for applications in biotechnology, diagnosis and antiviral properties in Africa; focus on application in agriculture
Nanobodies and their potential applications | Nanomedicine
Microorganisms | Free Full-Text | A Small Virus to Deliver Small Antibodies: New Targeted Therapies Based on AAV Delivery of Nanobodies | HTML
Nanobodies as Versatile Tools to Understand, Diagnose, Visualize and Treat Cancer - eBioMedicine
Johannes Passecker 5 classes of immunoglobins ~ 150 kilo Dalton (kDa) in size Main structure is very conserved: two identical 50kD heavy. - ppt download
Llama Single Domain Antibody Platform | Antibody Design Labs
Antibody engineering techniques of camelid heavy-chain antibodies
Camelid antibodies contain only heavy chains | Chromotek
Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG | Nature Communications
Frontiers | Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics | Oncology
Fully Human VH Single Domains That Rival the Stability and Cleft Recognition of Camelid Antibodies* - Journal of Biological Chemistry
Nanobodies: The Future of Antibody-Based Immune Therapeutics | Cancer Biotherapy and Radiopharmaceuticals